BioCardia, Inc.(BCDA)Earnings, Financials & Key RatiosBioCardia, Inc. (BCDA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
000 indicate an imminent risk of insolvency that outweighs the potential clinical value of its proprietary delivery platform.
BioCardia, Inc. (BCDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
BioCardia, Inc. (BCDA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.21vs $0.17-23.5% | — |
| Q2 2026 | Mar 24, 2026 | $0.06vs $0.20+70.0% | —vs $25,000 |
| Q4 2025 | Nov 12, 2025 | $0.24vs $0.25+4.0% | — |
| Q3 2025 | Aug 11, 2025 | $0.40vs $0.25-60.0% | — |
Recent stock market news and headlines for BioCardia, Inc. (BCDA)
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders.
Key metrics vs top competitors for BioCardia, Inc. (BCDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.02 | $5.89M | -0.83 | -100% | — | -950.12% | — | |
| $8.14 | $78.41M | 12.72 | — | -4088.84% | -127.3% | — | |
| $15.87 | $212.67M | -20.88 | -5.91% | -9.52% | -7.74% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $46.95 | $2.4B | 146.72 | 16.45% | 7.35% | 6.41% | — |
BioCardia, Inc. (BCDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BioCardia, Inc. (BCDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 21, 2026·SEC
May 15, 2026·SEC
May 8, 2026·SEC
Get notified when BCDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioCardia, Inc. (BCDA) stock FAQ — growth, dividends, profitability & financials explained
BioCardia, Inc. (BCDA) saw revenue decline by 100.0% over the past year.
BioCardia, Inc. (BCDA) reported a net loss of $7.8M for fiscal year 2025.
BioCardia, Inc. (BCDA) has a return on equity (ROE) of -950.1%. Negative ROE indicates the company is unprofitable.
BioCardia, Inc. (BCDA) had negative free cash flow of $7.5M in fiscal year 2025, likely due to heavy capital investments.
